CDK2-IN-28

Cat. No.:	HY-161463	0 ⁼ S ⁼⁰
CAS No.:	3025006-64-5	
Molecular Formula:	C ₂₅ H ₃₅ N ₇ O ₃ S	
Molecular Weight:	513.66	
Target:	CDK	\rangle N \rightarrow
Pathway:	Cell Cycle/DNA Damage	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	HN

BIOLOGICAL ACTIV	CDK2-IN-28 (compound 22) is a CDK2 inhibitor with good selectivity and cellular effects against other CDKs. CDK2-IN-28 has anti-proliferative effects on MKN1 cells (EC50: 0.31 µM), ^{[10][1]} .				
IC ₅₀ & Target	CDK7 54.7 nM (Ki, [1])	CDK2 1 nM (Ki, [1])	CDK5 15.8 nM (Ki, [1])	CDK9 12.8 nM (Ki, [1])	
In Vitro	CDK2-IN-28 (37 nM-3 μM; 24 h) significantly down-regulates the level of Rb phosphorylation at Ser807/811 and Ser780 in MKN1 cells ^[1] . CDK2-IN-28 (333.3 nM; 24 h) CDK2 inhibition in MKN1 cells causes cell cycle arrest in the G2/M phase ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis ^[1]				
	Cell Line:	MKN1 cells			
	Concentration:	37 nM, 111.1 nM, 333.3 nM, 1000 nM, 3000 nM			
	Incubation Time:	24 h			
	Result:	Significantly downregulated Rb phosphorylation at Ser807/811 and Ser780 in dose dependent way.			
	Cell Cycle Analysis ^[1]				
	Cell Line:	MKN1 cells			
	Concentration:	111.1 nM and 333.3 nM			
	Incubation Time:	24 h			
	Result:	Caused by CDK2 inhibition is accumulation of G0/G1 cells as the CDK2/cyclin E-mediated phosphorylation of Rb relieves suppression of the E2Fs, thus allowing G1/S transition through the restriction point.			
In Vivo	CDK2-IN-28 (10 mg/kg; po; single dose) provides poor plasma exposure in mouse, and CDK2-IN-28 (1 mg/kg; iv; single d also shows high plasma clearance (159-236 ml /min/kg) in mouse PK assav ^[1] .				

also shows high plasma clearance (159-236 mL/min/kg) in mouse PK assay $^{[1]}$.



MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Niu P, et al. Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors. Bioorg Med Chem. 2024 Apr 15;104:117711.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA